Abstract:Obesity has been linked with increased incidence and worse outcomes of at least 13 human cancers. For other cancers, our understanding of their relationship with obesity is more nebulous, with contradictory observations from different studies. An example is lung cancer. Central or visceral obesity is defined as accumulation of excess or abnormal fat in body that is harmful to its health. But in lung cancer, overweight and obesity, as defined by body mass index (BMI), is associated with reduced cancer risk and longer survival after treatment by surgery. In addition, some studies suggest that lung cancer in obese patients responds better to treatment with immune checkpoint inhibitors (ICIs) than in the non-obese. Apart from interesting biological questions, this "obesity paradox" presents practical issues in cancer prevention and clinical management, starting with the fundamental question of whether weight loss should be recommended in these contexts. Our investigations suggest that the incongruence between the observed benefits of obesity and its expected detrimental nature is likely the result of two main confounding factors in lung cancer studies. The first major confounding factor which we noticed is that certain commonly used medications have a secondary anti-cancer effect that is obesity-dependent. This is exemplified by the anti-diabetic metformin, which was prescribed 90 million times in 2021 in the US. We found that metformin use was associated with decreased likelihood of recurrence of early-stage lung cancer after resection, but only in overweight/obese patients (BMI > 25). Additionally, in late-stage cancer, metformin use by such patients correlated with a decrease in immune checkpoint molecules in their tumors, whereas an opposite effect of metformin use was seen in patients with lower BMI ( 90% of lung cancer. A retrospective analysis of more than 500 such patients who were treated with ICIs in our institution showed that this is indeed the case. Consistent with our mouse studies, disease progression among the ICI-treated patients was slowed by metformin in only overweight/obese patients. This set of observations raises the possibility that obesity-dependent anti-cancer effects similar to metformin's may exist for other commonly used drugs, especially those impacting cellular metabolism. Indeed, we found this to be the case for statins. In one study of approximately 600 early-stage non-small cell lung cancer patients who had resective surgery at our institution, use of statins was associated with longer recurrence-free survival in overweight/obese but not other patients. Our observations on confounding by metformin and statins show that the use of such medications has to be accounted for if the effect of obesity on cancer behavior is to be estimated in clinical or epidemiological studies. The other major confounding factor is the use of BMI as a measure of obesity. The validity of BMI as a sole measure of obesity is increasingly being questioned because it does not accurately capture body fat content or its heterogeneity and distribution, which are also biologically relevant. We find this to be the case in lung cancer as well. In a case-control study for which we used routine computerized tomographic (CT) images to accurately measure the body's fat content, we found that patients with early-stage lung cancer have more fat, but not higher BMI, than subjects without lung cancer but at high risk for the disease. Correspondingly, in mice, we and others have found that diet-induced obesity increases lung carcinogenesis by urethane and oncogenic Kras. This accelerated tumor growth is accompanied by enhanced suppressor leukocyte pools in the lung. To test if compromised immune surveillance could underpin the increased risk of cancer seen in obese patients, we characterized the leukocytes recovered from bronchoalveolar lavage fluids of subjects determined obese and non-obese by CT image analysis. Consistent with our hypothesis, and with our assessment of the lung immune cells of obese and non-obese mice, obese subject -Abstract Truncated-

Metabolic Dysregulation Explains the Diverse Impacts of Obesity in Males and Females with Gastrointestinal Cancers

Impact of Sex Differences on Cross- Talk Between the Gut Microbiome, CEACAMs, and TGF-β Signaling in Cancers

Abstract SY38-01: Diverse effects of obesity on cancer immunology and therapy: Both the good and the bad

X or Y Cancer: An Extensive Analysis of Sex Differences in Lung Adenocarcinoma

Sex-Specific Effects of Body Composition on Tumor Microenvironment in Non–Small Cell Lung Cancer

Sex Differences in the Incidence of Obesity-Related Gastrointestinal Cancer

Obesity and Cancer Treatment Outcomes: Interpreting the Complex Evidence

Abstract 3406: Transcriptomic analysis reveals differentially expressed pathways in colon tumors of cancer patients with vs without obesity: Results from the ColoCare Study

Obesity is associated with altered tumor metabolism in metastatic melanoma

Abstract PO1-14-06: Integrated analysis reveals the impact of obesity on triple-negative breast cancer

Abstract 2190: Transcriptomic signatures of obesity-driven colon cancer: A multi-species transdisciplinary approach

Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer

Obesity Contributes to Ovarian Cancer Metastatic Success Through Increased Lipogenesis, Enhanced Vascularity, and Decreased Infiltration of M1 Macrophages

The impact of obesity and adipokines on breast and gynecologic malignancies

Abstract SY38-02: Clinical investigations of obesity in cancer: BMI and other confounders

Exploring the Impact of the Obesity Paradox on Lung Cancer and Other Malignancies

A Combined Effect of Expression Levels of Obesity-Related Genes and Clinical Factors on Cancer Survival Rate

Body Weight Correlates with Molecular Variances in Cancer Patients

Abstract 3403: Disentangling the obesity paradox in high-grade serous epithelial ovarian cancer

Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity